Literature DB >> 7226109

Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients.

M S Didolkar, R A Bescher, E G Elias, R H Moore.   

Abstract

To study the biologic behavior and natural history of this rare but challenging tumor faced by oncologists, a clinicopathologic study of 42 patients with histologically proven adrenal cortical carcinoma from Roswell Park Memorial Institute (1929--1977) was done. These constituted .04% of all cancer cases and 0.2% of all autopsy cases. Age range was 3--74 years with median of 53 years; female to male ratio was 1.5 to 1. Clinical manifestations were: abdominal mass (36%), metastatic disease (30%), hormonal excess (17%) and weakness with lethargy (17%). Nine of ten functioning tumors were seen in female patients. Tumors arose in left adrenal in 26 patients, right adrenal in 12, and in four the site could not be determined because of bilateral presence of cancer. Median duration of symptoms was six months. At diagnosis, 52% had distant metastases, 41% had locally advanced tumor and 7% had tumor confined to adrenal. Sixteen patients underwent "curative" resection. Tumor diameter ranged from 1--30 cm with median of 10 cm. Of 28 patients who received different chemotherapeutic regimens, three (11%) had objective response; four of ten patients had objective response to radiation therapy. Overall median and five-year survival rates were 14 months and 24%. Prolonged survival (P less than .05) was noted in women, patients who had "curative" resection, a disease-free interval of more than 12 months, and tumor size greater than 10 cm diameter. Patients with functional tumors had longer median survival than those with non-functional ones (28 vs. 12), but P value was greater than .05. A second primary cancer was noted in 22.4% of cases, breast and lymphoma being the most common. At autopsy in 31 patients, the most common metastatic sites were retroperitoneal lymph nodes 68%, lung 71%, liver 42%, and bone 26%. To improve survival, an aggressive surgical approach is recommended to extirpate the tumor with involved organs and retroperitoneal lymph nodes. Adrenal carcinoma should be suspected in patients with metastatic cancer with an occult primary.

Entities:  

Mesh:

Year:  1981        PMID: 7226109     DOI: 10.1002/1097-0142(19810501)47:9<2153::aid-cncr2820470908>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  [Routine after-care 16 years after left adrenalectomy for adrenal cortex carcinoma. Late pulmonary metastasis of resected adrenal cortex carcinoma].

Authors:  M A Weber; S Delorme
Journal:  Radiologe       Date:  2002-03       Impact factor: 0.635

2.  An unusual case of adrenal cortical carcinoma.

Authors:  G R Mufti; J Farrell
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

Review 3.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

6.  Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma.

Authors:  Javier Valero-Elizondo; Yuhree Kim; Jason D Prescott; Georgios A Margonis; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

7.  A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.

Authors:  Mouhammed Amir Habra; Shamim Ejaz; Lei Feng; Prajnan Das; Ferhat Deniz; Elizabeth G Grubbs; Alexandria Phan; Steven G Waguespack; Montserrat Ayala-Ramirez; Camilo Jimenez; Nancy D Perrier; Jeffrey E Lee; Rena Vassilopoulou-Sellin
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

8.  Hyperadrenalism in childhood and adolescence.

Authors:  C G Thomas; A T Smith; J M Griffith; F B Askin
Journal:  Ann Surg       Date:  1984-05       Impact factor: 12.969

Review 9.  Nonfunctional adrenal cortical carcinoma. Report of a case and review of the literature.

Authors:  E D Fokaefs; M D Melekos; M P Melachrinou; I E Zarakovitis; G A Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

10.  Adrenocortical oncocytoma: case report with immunocytochemical and ultrastructural study.

Authors:  L R Bégin
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.